Cardiovascular Drugs Practice Questions

Q: Which one of the following is not an adverse effect of ACE inhibitors?

Hypokalemia. **Explanation:** **Why Hypokalemia is the Correct Answer:** ACE inhibitors (ACEIs) block the conversion of Angiotensin I to Angiotensin II. Since Angiotensin II is a potent stimulator of **aldosterone** secretion from the adrenal cortex, its inhibition leads to decreased aldosterone levels. Aldosterone normally promotes sodium reabsorption and potassium excretion in the distal tubule; therefore, ACEIs cause potassium retention, leading to **Hyperkalemia**, not hypokalemia. This is a critical side effect, especially in patients with chronic kidney disease or those taking potassium-sparing diuretics. **Analysis of Incorrect Options:** * **A. Cough:** This is the most common side effect (approx. 10%). ACEIs prevent the breakdown of **bradykinin** and Substance P in the lungs, leading to their accumulation, which sensitizes cough receptors. * **C. Angioneurotic edema:** A rare but life-threatening side effect caused by the accumulation of bradykinin, leading to rapid swelling of the lips, tongue, and glottis. * **D. Skin rash:** Common with Captopril, often attributed to its sulfhydryl group, though it can occur with other ACEIs as well. **NEET-PG High-Yield Pearls:** * **Mnemonic for ACEI side effects (CAPTOPRIL):** **C**ough, **A**ngioedema, **P**roteinuria/ **P**otassium excess, **T**aste changes, **O**rthostatic hypotension, **P**regnancy (Teratogenic), **R**ash, **I**ncreased renin, **L**eukopenia. * **Teratogenicity:** ACEIs are contraindicated in pregnancy as they cause **fetal renal dysgenesis** and skull hypoplasia. * **Drug of Choice:** ACEIs are the first-line treatment for hypertension in patients with **Diabetes Mellitus** due to their renoprotective effects (reduction of efferent arteriolar resistance).

Q: With respect to ticlopidine, which of the following is true for clopidogrel?

Is less likely to cause neutropenia. Ticlopidine and clopidogrel are both **P2Y12 receptor antagonists** (thienopyridines) that inhibit ADP-induced platelet aggregation. While they share a similar mechanism of action, clopidogrel was developed as a second-generation agent specifically to improve the safety profile. **1. Why Option B is Correct:** The most significant clinical difference between the two is the risk of **hematological toxicity**. Ticlopidine is associated with life-threatening **neutropenia** (approximately 1% of patients) and agranulocytosis, requiring frequent CBC monitoring during the first three months of therapy [1]. Clopidogrel has a significantly lower incidence of neutropenia, making it the preferred clinical choice. **2. Why Incorrect Options are Wrong:** * **Option A:** Neither drug is typically associated with the formation of antiplatelet antibodies (this is more characteristic of Heparin-Induced Thrombocytopenia). * **Option C:** Clopidogrel does not inherently cause more severe bleeding than ticlopidine; their bleeding risks are comparable when used at standard therapeutic doses. * **Option D:** Both drugs are prodrugs that require hepatic activation (via CYP450). While clopidogrel is more potent and has a faster onset of action, the primary reason for its preference in clinical practice is its superior safety profile rather than a vastly "greater" antiplatelet ceiling. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Irreversible inhibition of P2Y12 ADP receptors, leading to decreased activation of the GPIIb/IIIa complex. * **Toxicity:** Ticlopidine causes neutropenia and **TTP** (Thrombotic Thrombocytopenic Purpura) [1]. Clopidogrel can also cause TTP, but it is much rarer. * **Pharmacogenetics:** Clopidogrel is a prodrug activated by **CYP2C19**. Patients who are "poor metabolizers" of this enzyme (or those taking **Omeprazole**, a CYP2C19 inhibitor) will have reduced antiplatelet efficacy [2].

Q: Which of the following antihypertensives is used in premenstrual syndrome?

Clonidine. **Explanation:** **Clonidine** is a centrally acting **$\alpha_2$-adrenergic agonist**. While primarily used as an antihypertensive, it is effective in managing **Premenstrual Syndrome (PMS)** and menopausal symptoms. The underlying medical concept involves its ability to reduce sympathetic outflow and modulate neuroendocrine fluctuations. Specifically, it helps alleviate vasomotor symptoms (hot flashes), irritability, and certain physical discomforts associated with the luteal phase of the menstrual cycle. **Analysis of Incorrect Options:** * **Hydralazine:** A direct-acting vasodilator used primarily in hypertensive emergencies and pregnancy-induced hypertension (PIH). It has no role in hormonal or symptomatic management of PMS. * **Losartan:** An Angiotensin II Receptor Blocker (ARB). It is used for chronic hypertension and diabetic nephropathy but does not cross the blood-brain barrier effectively or influence the symptoms of PMS. * **Amlodipine:** A Calcium Channel Blocker (CCB) used for hypertension and angina. It acts on peripheral vascular smooth muscle and lacks the central neuromodulatory effects required to treat PMS. **High-Yield Clinical Pearls for NEET-PG:** * **Other uses of Clonidine:** Opioid withdrawal (reduces sympathetic overactivity), ADHD, Tourette syndrome, and prophylaxis of migraine. * **Side Effects:** Sedation, mental depression, and **marked dryness of mouth**. * **Rebound Hypertension:** Sudden withdrawal of clonidine can lead to a hypertensive crisis due to a massive release of stored catecholamines. * **Drug of Choice for PMS:** While clonidine is an option, **SSRIs** (like Fluoxetine) are generally considered the first-line pharmacological treatment for severe PMS/PMDD.

Q: Which of the following statements about hydralazine is NOT true?

It causes dilatation of both arteries and veins.. **Explanation:** Hydralazine is a **direct-acting vasodilator** primarily used in the management of hypertensive emergencies (especially in pregnancy) and chronic heart failure (in combination with nitrates). **1. Why Option B is the correct answer (The False Statement):** Hydralazine is a **selective arterial vasodilator**. It acts directly on the smooth muscles of the arterioles but has **minimal to no effect on the venous system** (veins). Because it does not cause venodilation, it does not significantly decrease preload or cause the peripheral venous pooling that leads to orthostatic hypotension. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** Hydralazine causes **direct relaxation** of vascular smooth muscle, likely by interfering with calcium metabolism and increasing local nitric oxide levels. * **Option C:** Since hydralazine does not affect the venous capacitance vessels, **postural (orthostatic) hypotension is rare**, unlike with alpha-blockers or nitrates. * **Option D:** Arteriolar dilation triggers a **baroreceptor-mediated sympathetic surge**. This leads to reflex tachycardia and an **increase in plasma renin activity**, causing sodium and water retention. This is why it is often co-administered with a beta-blocker and a diuretic. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** A classic side effect of hydralazine, especially in **slow acetylators**. It is associated with **Anti-Histone Antibodies**. * **Drug of Choice:** It is a preferred parenteral drug for **Hypertension in Pregnancy** (Preeclampsia/Eclampsia). * **Combination Therapy:** When combined with **Isosorbide Dinitrate (BiDil)**, it has been shown to improve mortality in African-American patients with heart failure.

Q: Which of the following drugs is NOT used in the management of chronic heart failure?

Isosorbide dinitrate. **Explanation:** The management of Chronic Heart Failure (CHF) focuses on drugs that provide a **mortality benefit** by inhibiting maladaptive neurohormonal remodeling (the RAAS and sympathetic nervous system). **Why Isosorbide Dinitrate is the correct answer:** While nitrates are potent vasodilators, **Isosorbide dinitrate (ISDN) alone** is typically used for symptomatic relief in acute heart failure or angina. In chronic heart failure, it does not provide a significant survival benefit when used as monotherapy. It is only recommended for chronic management when **combined with Hydralazine** (BiDil), specifically in patients of African-American descent or those intolerant to ACE inhibitors/ARBs [1, 2]. **Analysis of Incorrect Options:** * **Lisinopril (ACE Inhibitor):** These are first-line agents in CHF. they decrease preload and afterload and, most importantly, prevent cardiac remodeling, significantly reducing mortality [1]. * **Spironolactone (Mineralocorticoid Receptor Antagonist):** It blocks the effects of aldosterone. Clinical trials (like RALES) have proven it reduces mortality and hospitalization in patients with NYHA Class II-IV heart failure [1]. * **Losartan (ARB):** Used as an alternative to ACE inhibitors (especially if the patient develops a cough). Like ACE inhibitors, ARBs provide a mortality benefit by blocking the RAAS pathway [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs improving survival in CHF:** ACE inhibitors, ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Drugs only for symptomatic relief (No mortality benefit):** Digoxin, Loop diuretics (Furosemide), and Ionotropes (Dopamine/Dobutamine) [1]. * **Hydralazine + ISDN:** The only nitrate combination proven to reduce mortality in specific populations (African-Americans) [1, 2].

Q: Which of the following is a new drug that acts by inhibiting PCSK9?

Alirocumab. **Explanation:** **Alirocumab** is a human monoclonal antibody that acts as a **PCSK9 inhibitor**. **Mechanism of Action:** PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) is an enzyme that binds to LDL receptors (LDL-R) on the surface of hepatocytes and promotes their degradation. By inhibiting PCSK9, Alirocumab increases the number of available LDL receptors on the liver cell surface. This leads to increased clearance of LDL-cholesterol from the blood, significantly lowering plasma LDL levels. It is primarily used in patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL lowering. **Analysis of Incorrect Options:** * **Reslizumab (A):** An interleukin-5 (IL-5) antagonist used as add-on maintenance treatment for severe eosinophilic asthma. * **Brodalumab (B):** An interleukin-17 (IL-17) receptor antagonist used in the treatment of moderate-to-severe plaque psoriasis. * **Ixekizumab (D):** Another IL-17A inhibitor used for plaque psoriasis and psoriatic arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **PCSK9 Inhibitors:** Include **Alirocumab** and **Evolocumab**. They are administered via subcutaneous injection every 2–4 weeks. * **Efficacy:** They can reduce LDL-C by up to 50–70%, even in patients already on maximal statin therapy. * **Inclisiran:** A newer agent (small interfering RNA or siRNA) that also targets PCSK9 synthesis in the liver but has a longer duration of action (dosed every 6 months). * **Adverse Effects:** Generally well-tolerated; most common side effects include injection site reactions and nasopharyngitis.

Q: Sildenafil (Viagra) produces its physiological effects by blocking the enzyme that hydrolyzes the second messenger by which nitric oxide produces its physiological effects. What is this second messenger?

Cyclic GMP. **Explanation:** **Mechanism of Action:** Nitric Oxide (NO) is a potent vasodilator released from vascular endothelial cells. It activates the enzyme **Guanylate Cyclase**, which converts GTP into **Cyclic GMP (cGMP)**. cGMP acts as the **second messenger** that triggers protein kinase G, leading to smooth muscle relaxation and increased blood flow (vasodilation). In the corpus cavernosum, this process results in penile erection. Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**, the enzyme responsible for the hydrolysis (breakdown) of cGMP. By blocking PDE-5, Sildenafil prevents the degradation of cGMP, prolonging its vasodilatory effects. **Analysis of Incorrect Options:** * **A. Bradykinin:** This is a potent vasodilator peptide, not a second messenger. It works by stimulating the release of NO and prostacyclin. * **C. Protein kinase A:** This is the downstream effector for the **cAMP** pathway (e.g., stimulated by Beta-agonists), not the cGMP pathway. * **D. Endothelin:** This is a potent endogenous **vasoconstrictor** peptide, acting in opposition to the effects of Nitric Oxide. **High-Yield NEET-PG Pearls:** * **Drug Interaction:** Sildenafil is strictly contraindicated with **Nitrates** (e.g., Nitroglycerin) because both increase cGMP through different mechanisms, leading to synergistic peripheral vasodilation and life-threatening hypotension. * **Other PDE-5 Inhibitors:** Tadalafil (longer half-life, "the weekend pill") and Vardenafil. * **Other Indications:** PDE-5 inhibitors are also used in the management of **Pulmonary Arterial Hypertension (PAH)**. * **Side Effect:** "Blue vision" (cyanopsia) occurs due to weak inhibition of PDE-6 in the retina.

Q: What is the most common side effect of dihydropyridine calcium channel blockers?

Headache. **Explanation:** Dihydropyridine (DHP) Calcium Channel Blockers (CCBs), such as **Amlodipine** and **Nifedipine**, act primarily by inhibiting L-type calcium channels in the vascular smooth muscle. This leads to potent **peripheral vasodilation**. **1. Why Headache is the correct answer:** The primary mechanism of DHP-CCBs is the relaxation of arterial smooth muscle. This causes significant vasodilation of the meningeal and cerebral vessels. The resulting increase in intracranial blood flow and stretching of vessel walls triggers sensory nerves, leading to **vasodilatory headaches**. This is the most frequently reported side effect, especially during the initiation of therapy. Other common side effects due to this same mechanism include **peripheral edema** (due to precapillary dilation) and **flushing**. **2. Why the other options are incorrect:** * **B. Constipation:** This is a classic side effect of **Verapamil** (a non-dihydropyridine CCB). Verapamil inhibits calcium channels in the gastrointestinal smooth muscle, leading to decreased motility. It is rarely seen with DHPs. * **C. Diarrhoea:** This is not a characteristic side effect of CCBs. In fact, CCBs are more likely to cause decreased bowel motility. * **D. Muscle cramps:** While occasionally reported, these are not a "most common" or "classic" side effect compared to the vascular symptoms of DHPs. **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Edema:** A highly characteristic side effect of Amlodipine; it is **not** due to fluid overload but due to increased capillary hydrostatic pressure (pre-capillary dilation). * **Reflex Tachycardia:** Common with short-acting DHPs (like Nifedipine) due to rapid vasodilation triggering the baroreceptor reflex. * **Gingival Hyperplasia:** A shared side effect of CCBs (especially Nifedipine), Phenytoin, and Cyclosporine.

Question 1

Which one of the following is not an adverse effect of ACE inhibitors?

Accepted Answer

Hypokalemia

Answer

Cough

Answer

Angioneurotic edema

Answer

Skin rash

Question 2

With respect to ticlopidine, which of the following is true for clopidogrel?

Accepted Answer

Is less likely to cause neutropenia

Answer

Is more likely to cause formation of antiplatelet antibodies

Answer

Is more likely to cause severe bleeding

Answer

Has a greater antiplatelet effect

Question 3

Which of the following antihypertensives is used in premenstrual syndrome?

Accepted Answer

Clonidine

Answer

Hydralazine

Answer

Losartan

Answer

Amlodipine

Question 4

Which of the following statements about hydralazine is NOT true?

Accepted Answer

It causes dilatation of both arteries and veins.

Answer

It causes direct relaxation of blood vessels.

Answer

Postural hypotension is not a common problem.

Answer

It increases plasma renin activity.

Question 5

Which of the following drugs is NOT used in the management of chronic heart failure?

Accepted Answer

Isosorbide dinitrate

Answer

Lisinopril

Answer

Spironolactone

Answer

Losartan

Question 6

Which of the following is a new drug that acts by inhibiting PCSK9?

Accepted Answer

Alirocumab

Answer

Reslizumab

Answer

Brodalumab

Answer

Ixekizumab

Question 7

Which of the following calcium channel blockers is indicated for increased intracranial tension?

Accepted Answer

Nimodipine

Answer

Nicardipine

Answer

Clevidipine

Answer

Nitrendipine

Question 8

A 42-year-old woman with a 20-year history of Type II diabetes has hypertension with a BP in the 150/94 mmHg range and mild proteinuria on urinalysis. Which drug would be the best to treat the hypertension in this individual?

Accepted Answer

Enalapril

Answer

Hydrochlorothiazide

Answer

Propranolol

Answer

Nifedipine

Question 9

Sildenafil (Viagra) produces its physiological effects by blocking the enzyme that hydrolyzes the second messenger by which nitric oxide produces its physiological effects. What is this second messenger?

Accepted Answer

Cyclic GMP

Answer

Bradykinin

Answer

Protein kinase A

Answer

Endothelin

Question 10

What is the most common side effect of dihydropyridine calcium channel blockers?

Accepted Answer

Headache

Answer

Constipation

Answer

Diarrhoea

Answer

Muscle cramps

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?